Am J Perinatol 2006; 23(6): 377-380
DOI: 10.1055/s-2006-948223
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Management of Uterine Hyperstimulation with Concomitant Use of Oxytocin and Terbutaline

Luis D. Pacheco1 , Mitchell P. Rosen2 , Alfredo F. Gei1 , George R. Saade1 , Gary D.V Hankins1
  • 1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
  • 2Department of Obstetrics and Gynecology, The University of California, San Francisco, California
Further Information

Publication History

Publication Date:
17 July 2006 (online)

ABSTRACT

The purpose of this study was to evaluate the efficacy of the concomitant use of subcutaneous terbutaline and oxytocin for the management of uterine hyperstimulation. Patients in active labor receiving intravenous oxytocin who developed uterine hyperstimulation were randomly assigned to receive either oxytocin discontinuation or administration of subcutaneous terbutaline while maintaining the oxytocin infusion. Time to resolution of hyperstimulation was the primary end point. Twenty-nine patients were enrolled. The most frequent types of hyperstimulation were tachysystole (26%) and mixed patterns (26%). Resolution time was significantly shorter in the combination therapy versus control (p = 0.002). Persistence of hyperstimulation 15 minutes after intervention was seen in 53% of the women in the control group versus 0% of the women in the study group. No significant differences were noted in the Apgar scores, rates of cesarean sections, or chorioamnionitis. In the management of uterine hyperstimulation, subcutaneous terbutaline without discontinuation of oxytocin is more effective than the traditional approach of oxytocin discontinuation.

REFERENCES

  • 1 Committee on Practice Bulletins-Obstetrics . Dystocia and augmentation of labor.  Int J Gynaecol Obstet. 2004;  85 315-324
  • 2 Sanchez-Ramos L, Gaudier F L, Kaunitz A M. Cervical ripening and labor induction after previous cesarean delivery.  Clin Obstet Gynecol. 2000;  43 513-523
  • 3 Lipshitz J, Klose C W. Use of tocolytic drugs to reverse oxytocin induced uterine hypertonus and fetal distress.  Obstet Gynecol. 1985;  66 16S-18S
  • 4 Curtis P, Evens S, Resnick J. Uterine hyperstimulation: the need for standard terminology.  J Reprod Med. 1987;  32 91-95
  • 5 Chua S, Kurup A, Arulkumaran S, Ratnam S S. Augmentation of labor: does internal tocography result in better obstetric outcome than external tocography?.  Obstet Gynecol. 1990;  76 164-167
  • 6 Valenzuela G J, Foster T C. Use of magnesium sulphate to treat hyperstimulation in term labor.  Obstet Gynecol. 1990;  75 762-764
  • 7 Cabaniss M. Uterine activity. In: Cabaniss M Fetal Monitoring Interpretation. Philadelphia, PA; Lippincott Williams & Wilkins 1993: 335-381
  • 8 Siimes A S, Creasy R K. Effect of ritodrine on uterine activity, heart rate and blood pressure in the pregnant sheep: combined use of alpha or beta blockade.  Am J Obstet Gynecol. 1976;  126 1003-1010

Luis D PachecoM.D. 

Fellow, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Medical Branch

301 University Blvd., Galveston, TX 77555-0587

    >